Quarterly ResultAug 12, 2026, 08:31 AM
Dyadic Q2 Revenue $961K, Net Loss $(2.12)M; Commercial Progress
AI Summary
Dyadic International reported Q2 2026 financial results with total revenue of $961,138, a slight decrease of 0.6% year-over-year, and a net loss of $(2,123,884), or $(0.06) per share. The company highlighted significant progress in product commercialization, including shipments of recombinant proteins and initial pilot sales for cultivated-meat applications. Strategic partnerships with Proliant Health & Biologicals, Fermbox Bio, and Inzymes are advancing, with new product commercializations and expanded portfolios. However, cash and equivalents decreased to $4.79 million, and operating loss increased by 18.8%.
Key Highlights
- Q2 2026 total revenue was $961,138, a 0.6% decrease YoY.
- Q2 2026 net loss was $(2,123,884), or $(0.06) per share.
- Cash, equivalents, and securities totaled $4.79M as of June 30, 2026.
- R&D expenses decreased 47.2% to $332,621 in Q2 2026.
- G&A expenses increased 17.6% to $1,689,863 in Q2 2026.
- Advanced recombinant protein portfolio with Q2 product shipments and initial pilot sales.
- Proliant Health & Biologicals began commercialization of Albufree™ DX.
- Fermbox Bio scaled commercialization for recombinant DNase I and transferrin.
Price Impact
More from DYAI